ClinicalTrials.gg

alpha 1-Antitrypsin Deficiency clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 142 studies for alpha 1-Antitrypsin Deficiency across more than 10 countries. 32 are recruiting or about to start. 109 of them are mainly about alpha 1-Antitrypsin Deficiency (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

Status

Completed
66
Recruiting
24
Terminated
19
Status unknown
9
Withdrawn
8
Active, not recruiting
6

Phase

Phase 2
43
Phase 1
33
Phase 3
13
Phase 4
9
Early Phase 1
2

Where

United States
81
United Kingdom
28
Germany
24
Sweden
19
Canada
19
Australia
18

Who develops what

Add alpha 1-Antitrypsin Deficiency to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 7 companies, 7 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months. Compare BioMarin Pharmaceutical, CSL and Grifols here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
alpha 1-AntitrypsinRecent, repeated
Evidence
  • NCT05856331 · Sanofi · Phase 2 · comparator · “Zemaira” · registered Mar 2023
  • NCT05466747 · Takeda · Phase 4 · comparator · “Another Available A1PI” · registered Jun 2022
  • NCT03385395 · Octapharma · Phase 2 · comparator · “Glassia” · registered Dec 2017
Grifols50% of its industry studiesEU: CSL Limited (EMA 2015)22 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Alpha-1 15%☆ Track1 live phase-3 study: NCT07555483Grifols

The 1 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Sept 2027 est.Alpha-1 15% · Grifols · Phase 3 main aimNCT07555483 A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) — primary endpoint: Steady-state AUC of alpha1-PI over the weekly dosing interval (from 0 to 7 days) (AUC0-7 days) in the IV Treatment Period 1 and in the SC Treatment Period 2 for both dose levels · 40 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in alpha 1-Antitrypsin Deficiency studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

9studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 9, phase 3 first

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger. 4 (17%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 5 (21%) take healthy volunteers.

Recruiting studies that take each age, of 24
AgeWomenMen
104 (17%)4 (17%)
1823 (96%)23 (96%)
3024 (100%)24 (100%)
4024 (100%)24 (100%)
5024 (100%)24 (100%)
6524 (100%)24 (100%)
7518 (75%)18 (75%)
8513 (54%)13 (54%)

Across all 142 studies, recruiting or not: 37% stop at 75 or younger and 15% at 65; 15% take children; 1% are for women only and 1% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 142. Browse all 142 → or search them.